Auditory Verbal Hallucinations in Schizophrenia

Schizophrenia Clinical Trial

— HAV  

Official title:

Electromyography Study of Lip Muscles During Auditory Verbal Hallucinations Without Subvocalization in Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01886417
• Other study ID #: 0906
• Secondary ID: 2009-A00248-49
• Status: Completed
• Phase: N/A
• First received: June 21, 2013
• Last updated: March 9, 2015
• Start date: October 2009
• Est. completion date: March 2015

Study information

• Verified date: March 2015
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Observational

Clinical Trial Summary

Auditory verbal hallucinations (AVHs) are speech perceptions in the absence of a relevant external stimulation. Some accounts of AVHs claim that a deficit in inner speech monitoring would cause the verbal thoughts of the patient to be perceived as external voices resulting in AVHs.

In order to examine whether AVHs correspond to self-generated inner speech, the present study aims at collecting speech muscle activity during covert AVHs (without articulation), overt speech and rest. Surface electromyography (sEMG) is used on schizophrenia patients and control subjects to detect any speech muscle activity during AVH.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

Healthy controls:

• must be more than 18 years and less than 60 years old

• pre-inclusion medical examination

• must have signed consent form

• must be able to read stimuli on a screen

Schizophrenia patients:

• must be more than 18 years and less than 60 years old

• pre-inclusion medical examination

• must have signed consent form

• must be able to read stimuli on a screen

• diagnosed with a schizophrenia disorder according to DSM-IV TR (diagnostic and statistical of mental disorders) (PANSS item P3 greater than 4)

• prior evaluation of the secondary effects of any medication via Barnes and AIMS scales

• affiliated with the French social security

• if under guardianship, must have additional consent form signed by guardian

Exclusion Criteria:

Healthy controls:

• if aged less than 18 years or more than 60 years

• diagnosed with any psychiatric disorder

• with any language disorder (aphasia, SLI, dysarthria, stuttering, etc.)

• with auditory impairment

• pregnant, parturient, breast-feeding

Schizophrenia patients:

• if aged less than 18 years or more than 60 years

• significant secondary effects of antipsychotic medication, measured with the Barnes and AIMS scales

• with a neurodegenerative disease

• with any language disorder (aphasia, SLI, dysarthria, stuttering, etc.)

• with auditory impairment

• pregnant, parturient, breast-feeding

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Hallucinations
• Schizophrenia

Locations

Country	Name	City	State
France	University Hospital of Grenoble	Grenoble

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Grenoble	Speech and Cognition Department, GIPSA-lab

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Labial EMG activity during auditory verbal hallucination		up to 3 years	No